The overexpression of SOX18 in HCC can be attributed to the mechanism by which FGFR4 and its ligand, FGF19, activate the p-FRS2/p-GSK3β/β-catenin pathway to transactivate the SOX18 promoter directly [134]. This evidence concerns the gene FGF19 and hepatocellular carcinoma.